# Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

> **NCT00710970** · PHASE2 · COMPLETED · sponsor: **Seth Lerner** · enrollment: 28 (actual)

## Conditions studied

- Urinary Bladder Neoplasms

## Interventions

- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT00710970
- **Lead sponsor:** Seth Lerner
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-01-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00710970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00710970, "Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00710970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*